Discovery of New Commercially Valuable Antibiotics to Treat Bacterial Infection

Discuva’s technology provides a powerful platform to discover new classes of antibiotics which have major advantages over conventional antibiotics; reduced development of resistance, fewer side effects and longer market life. Small molecule antibiotics are first identified by high-throughput phenotypic screening of specialised compound collections. The robust proprietary platform technology is then used to identify the molecular target(s) and all genes associated with the development of resistance. The platform, which represents a major leap forward in antibiotics research, ensures that the antibiotics pursued into optimisation are those which have the best chance of reaching the clinic. Discuva has established its platform, identified initial hits against major Gram -ve pathogens and initiated discussions with Pharma. The objective is to progress compounds to lead status creating commercially attractive candidates ready for optimisation and development.